Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes

Ann Oncol. 2019 Nov 1;30(11):1682-1685. doi: 10.1093/annonc/mdz412.

Authors

A Sveen¹, C Cremolini², R Dienstmann³

Affiliations

¹ Division for Cancer Medicine, Department of Molecular Oncology, Institute for Cancer Research & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
² Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
³ Oncology Data Science, Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address: rdienstmann@vhio.net.

PMID: 31868904
DOI: 10.1093/annonc/mdz412

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab / pharmacology
Bevacizumab / therapeutic use
Biomarkers, Tumor / antagonists & inhibitors
Biomarkers, Tumor / genetics*
Camptothecin / analogs & derivatives*
Camptothecin / pharmacology
Camptothecin / therapeutic use
Cetuximab / pharmacology
Cetuximab / therapeutic use
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / genetics
Colorectal Neoplasms / mortality
Colorectal Neoplasms / pathology
Consensus
Female
Fluorouracil / pharmacology
Fluorouracil / therapeutic use
Gene Expression Profiling / standards
Gene Expression Regulation, Neoplastic*
Genetic Heterogeneity
Humans
Leucovorin / pharmacology
Leucovorin / therapeutic use
Male
Middle Aged
Models, Biological*
Molecular Targeted Therapy / methods
Patient Selection
Progression-Free Survival
Randomized Controlled Trials as Topic
Tumor Microenvironment / drug effects
Tumor Microenvironment / genetics

Substances

Biomarkers, Tumor
Bevacizumab
Cetuximab
Leucovorin
Fluorouracil
Camptothecin

Supplementary concepts

IFL protocol